Stockscreener 앱 받기
2.21
7.53%
-0.18
전일 마감가:
$2.39
열려 있는:
$2.39
하루 거래량:
183.11K
Relative Volume:
1.10
시가총액:
$83.12M
수익:
-
순이익/손실:
$-13.27M
주가수익비율:
-13.48
EPS:
-0.164
순현금흐름:
$-7.70M
1주 성능:
-19.93%
1개월 성능:
+17.55%
6개월 성능:
-25.34%
1년 성능:
+111.48%
1일 변동 폭
$2.20
$2.5286
1주일 범위
$2.20
$3.20
52주 변동 폭
$0.9016
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
OKYO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
2.21 | 89.89M | 0 | -13.27M | -7.70M | -0.164 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-08 | 개시 | B. Riley Securities | Buy |
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
Published on: 2026-01-18 23:27:28 - baoquankhu1.vn
Can Whitehawk Therapeutics Inc sustain its profitability2025 Pullback Review & Weekly Sector Rotation Insights - baoquankhu1.vn
OKYO Pharma (NASDAQ:OKYO) Trading Down 15.5%What's Next? - MarketBeat
Published on: 2026-01-13 10:43:18 - baoquankhu1.vn
Aug Technicals: Can OKYO Pharma Limited maintain sales growth2025 Stock Rankings & Verified Momentum Stock Ideas - baoquankhu1.vn
Risk Hedge: Can OKYO Pharma Limited stock beat analyst upgradesJuly 2025 Price Swings & Weekly High Return Stock Opportunities - moha.gov.vn
Is OKYO Pharma Limited stock affected by interest rate hikes2025 Growth vs Value & Weekly High Conviction Ideas - Улправда
Dividend Watch: Will OKYO Pharma Limited stock benefit from green energy trendsMarket Volume Report & Daily Profit Maximizing Tips - Улправда
Can OKYO Pharma Limited stock resist market sell offsSell Signal & Technical Confirmation Alerts - Улправда
Will OKYO Pharma Limited stock benefit from green energy trendsQuarterly Earnings Summary & Weekly Hot Stock Watchlists - Улправда
Can OKYO Pharma Limited stock beat analyst upgradesJuly 2025 Patterns & Real-Time Buy Signal Alerts - Улправда
Will OKYO Pharma Limited stock outperform growth indexesStop Loss & Detailed Earnings Play Strategies - Улправда
Will OKYO Pharma Limited stock benefit from automationEarnings Recap Summary & Weekly Setup with ROI Potential - Улправда
Will OKYO Pharma Limited stock recover faster than marketJuly 2025 WrapUp & Smart Money Movement Tracker - Улправда
Entry Recap: Can OKYO Pharma Limited stock beat analyst upgradesJuly 2025 PostEarnings & Fast Gain Swing Trade Alerts - Улправда
What Wall Street predicts for OKYO Pharma Limited stock priceQuarterly Trade Review & Weekly Top Stock Performers List - Улправда
Is OKYO Pharma Limited stock trading at a premium valuationTechnical Pattern Recognition & Identify Winning Stocks - Улправда
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target - Investing.com Nigeria
OKYO Pharma appoints Robert Dempsey as new CEO By Investing.com - Investing.com Nigeria
OKYO Pharma Limited's (NASDAQ:OKYO) Intrinsic Value Is Potentially 90% Above Its Share Price - Yahoo Finance
OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential - TipRanks
OKYO Pharma appoints Ophthalmology veteran Robert Dempsey as new CEO - Proactive financial news
OKYO Pharma names ophthalmology veteran Robert Dempsey as CEO - Proactive financial news
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer - BioSpace
OKYO Pharma names Robert J. Dempsey as chief executive officer By Investing.com - Investing.com Canada
OKYO Pharma names Robert J. Dempsey as chief executive officer - Investing.com
OKYO Pharma Names Ophthalmology Veteran Robert J. Dempsey as CEO to Drive Next Growth Phase - TipRanks
OKYO Pharma appoints Robert Dempsey as new CEO - Investing.com
OKYO Pharma names ophthalmology veteran Robert J Dempsey as CEO to drive next growth phase - MSN
Is Alico Inc stock a smart buy before Fed meetingRisk Management & Fast Exit and Entry Trade Guides - moha.gov.vn
Will OKYO Pharma Limited stock remain a Wall Street favoriteTrendline Breakouts & Free High Yield Portfolio Picks - bollywoodhelpline.com
Technical Analysis: What dividend safety score for OKYO Pharma Limited stockMarket Activity Recap & Fast Moving Stock Trade Plans - moha.gov.vn
OKYO Pharma reports positive phase 2 results for Urcosimod in neuropathic corneal pain - MSN
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update - MarketBeat
Will OKYO Pharma Limited stock maintain dividend yieldJuly 2025 Catalysts & Trade Opportunity Analysis Reports - Улправда
Volatility Watch: How OKYO Pharma Limited OK11 stock gains from tech spendingJuly 2025 Price Swings & Verified High Yield Trade Plans - moha.gov.vn
Bank Watch: What Wall Street predicts for OKYO Pharma Limited stock priceJuly 2025 Levels & Daily Chart Pattern Signals - Улправда
Will OKYO Pharma Limited (OK11) stock hit analyst forecastsMarket Trend Review & Weekly High Return Stock Opportunities - Улправда
Will OKYO Pharma Limited stock see PE expansionJuly 2025 Reactions & Stock Market Timing Techniques - Улправда
Small cap wrap: Gunnison Copper, OKYO Pharma, Abacus Global Management… - Proactive Investors
Is OKYO Pharma Limited (OK11) stock suitable for passive index fundsJuly 2025 EndofMonth & Weekly High Return Stock Forecasts - Улправда
OKYO Pharma management to ring Nasdaq opening bell in New York - Investing.com Australia
Pullback Watch: Why retail investors pile into OKYO Pharma Limited stock2025 Market WrapUp & AI Driven Stock Movement Reports - DonanımHaber
OKYO Pharma Ltd Rings the Nasdaq Stock Market Opening Bell - Nasdaq
OKYO Pharma Ltd Rings the Opening Bell - Nasdaq
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors
OKYO Pharma management to ring Nasdaq opening bell in New York By Investing.com - Investing.com South Africa
OKYO Pharma Rings Nasdaq Opening Bell as Urcosimod Advances After Positive Phase 2 NCP Data - TipRanks
Okyo Pharma Limited (OKYO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):